Anadys, Novartis Pull Plug On Toll-Like Receptor Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision does not affect agreement with Novartis to develop TLR7 agonists for hepatitis C and B and other infectious diseases, Anadys CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Hemispherx’s Ampligen Poised To Become First Approval For Chronic Fatigue Syndrome
FDA staff scheduling changes are behind a 1-2 week delay of action on May 25 user fee goal.
Hemispherx’s Ampligen Poised To Become First Approval For Chronic Fatigue Syndrome
FDA staff scheduling changes are behind a 1-2 week delay of action on May 25 user fee goal.
GlobeImmune’s Hep C Vaccine Posts Positive Phase II Data
GlobeImmune responds to calls to “show me the data,” increasing its chances of a partnership.